Yahoo Finance Global Alpha Emitters Market to Reach $2.6 Billion by 2030
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.
New York, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Alpha Emitters Industry" - https://www.reportlinker.com/p05955838/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Alpha Emitters Market to Reach $2.6 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Alpha Emitters estimated at US$561 Million in the year 2022, is projected to reach a revised size of US$2.6 Billion by 2030, growing at a CAGR of 21% over the analysis period 2022-2030. Bone Metastasis, one of the segments analyzed in the report, is projected to record a 20.5% CAGR and reach US$898.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ovarian Cancer segment is readjusted to a revised 22.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $164.1 Million, While China is Forecast to Grow at 19.7% CAGR
The Alpha Emitters market in the U.S. is estimated at US$164.1 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$426.9 Million by the year 2030 trailing a CAGR of 19.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 19.1% and 18.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 15.2% CAGR.
Select Competitors (Total 12 Featured)
- Actinium Pharmaceuticals, Inc.
- Alpha Tau Medical
- Bayer AG
- Fusion Pharma
- IBA Group
- IBA Radiopharma Solutions
- Lantheus Medical Imaging, Inc.
- NTP Radiosotopes SOC Ltd.
- RadioMedix, Inc.
- Siemens Healthineers
- Telix Pharmaceuticals Ltd.
- Triad Isotopes, Inc.
Read the full report: https://www.reportlinker.com/p05955838/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Alpha Emitters - Global Key Competitors Percentage Market Share
in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Alpha Emitters Market Analysis of Annual Sales
in US$ Thousand for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Alpha
Emitters by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 3: World 8-Year Perspective for Alpha Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2023 & 2030
Table 4: World Recent Past, Current & Future Analysis for Bone
Metastasis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 5: World 8-Year Perspective for Bone Metastasis by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 6: World Recent Past, Current & Future Analysis for
Ovarian Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 7: World 8-Year Perspective for Ovarian Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for
Pancreatic Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 9: World 8-Year Perspective for Pancreatic Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
Table 10: World Recent Past, Current & Future Analysis for
Melanoma by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2022 through
2030 and % CAGR
Table 11: World 8-Year Perspective for Melanoma by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2023 & 2030
Table 12: World Recent Past, Current & Future Analysis for
Other Applications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR
Table 13: World 8-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United States for 2023 (E)
Table 14: USA Recent Past, Current & Future Analysis for Alpha
Emitters by Application - Bone Metastasis, Ovarian Cancer,
Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 15: USA 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
CANADA
Table 16: Canada Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 17: Canada 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
JAPAN
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Japan for 2023 (E)
Table 18: Japan Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 19: Japan 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
CHINA
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in China for 2023 (E)
Table 20: China Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 21: China 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
EUROPE
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Europe for 2023 (E)
Table 22: Europe Recent Past, Current & Future Analysis for
Alpha Emitters by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
Table 23: Europe 8-Year Perspective for Alpha Emitters by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2023 & 2030
Table 24: Europe Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 25: Europe 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
FRANCE
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in France for 2023 (E)
Table 26: France Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 27: France 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
GERMANY
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Germany for 2023 (E)
Table 28: Germany Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 29: Germany 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
ITALY
Table 30: Italy Recent Past, Current & Future Analysis for
Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 31: Italy 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
UNITED KINGDOM
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in the United Kingdom for 2023 (E)
Table 32: UK Recent Past, Current & Future Analysis for Alpha
Emitters by Application - Bone Metastasis, Ovarian Cancer,
Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 33: UK 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
REST OF EUROPE
Table 34: Rest of Europe Recent Past, Current & Future Analysis
for Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 35: Rest of Europe 8-Year Perspective for Alpha Emitters
by Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
ASIA-PACIFIC
Alpha Emitters Market Presence - Strong/Active/Niche/Trivial -
Key Competitors in Asia-Pacific for 2023 (E)
Table 36: Asia-Pacific Recent Past, Current & Future Analysis
for Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 37: Asia-Pacific 8-Year Perspective for Alpha Emitters by
Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
REST OF WORLD
Table 38: Rest of World Recent Past, Current & Future Analysis
for Alpha Emitters by Application - Bone Metastasis, Ovarian
Cancer, Pancreatic Cancer, Melanoma and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR
Table 39: Rest of World 8-Year Perspective for Alpha Emitters
by Application - Percentage Breakdown of Value Sales for Bone
Metastasis, Ovarian Cancer, Pancreatic Cancer, Melanoma and
Other Applications for the Years 2023 & 2030
IV. COMPETITION
Read the full report: https://www.reportlinker.com/p05955838/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
